Searching for biomarker to evaluate endothelial dysfunction after drug-eluting stent implantation
| Project/Area Number |
26861536
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Emergency medicine
|
|---|
| Research Institution | Kurume University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | IL-1β / 薬剤溶出性ステント / 内皮機能障害 / mTOR / DES / バイオマーカー |
|---|
| Outline of Final Research Achievements |
Patients with mammalian target of rapamycin (mTOR)-inhibitor drug-eluting stent (DES) were reported to have impaired coronary endothelial function. There is no non-invasive biomarker of coronary endothelial dysfunction. Interleukin (IL)-1β is known to cause of endothelial dysfunction. We examined whether IL-1β were associated with coronary endothelial dysfunction after mTOR-inhibitor DES , and to investigate the possible mechanism.
Increased serum IL-1β could detect coronary endothelial dysfunction after DES implantation. mTOR inhibition triggers IL-1β release through transcriptional activation in CASMCs of stent site, which may lead to coronary endothelial dysfunction at distal to the stent.
|
Report
(3 results)
Research Products
(4 results)
